Where does Healthlead Corporation Limited rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Healthlead Corporation Limited ranks #17,737 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Healthlead Corporation Limited hold?

Healthlead Corporation Limited holds 16 US utility patents granted between 2022 and 2025, spanning 0 technology areas.

What is Healthlead Corporation Limited's Innovation Score?

Healthlead Corporation Limited has an Innovation Score of 30.4 out of 100 (34th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Healthlead Corporation Limited focus on?

Healthlead Corporation Limited holds grants across 0 technology areas classified under the Cooperative Patent Classification system.

Is Healthlead Corporation Limited's patent grant rate increasing or decreasing?

Insufficient historical data is available to calculate a velocity trend for Healthlead Corporation Limited.

What does claim depth mean for Healthlead Corporation Limited's patents?

Healthlead Corporation Limited's patents average 1.0 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Healthlead Corporation Limited patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Healthlead Corporation Limited

USPTO PatentsView assignee record - 16 granted patents across 0 technology areas, recorded in grant years 2022–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength.

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Healthlead ranks #17,737 of 49,997 tracked US assignees by granted-patent volume, with 16 patents across 0 technology areas.

#17,737
of 49,997 US assignees by volume: 34th percentile
by Innovation Score (30.4/100): 1.0
avg claims per patent

USPTO PatentsView assignee plate

Corpus R17737 · Foreign Corporation #17,737 · 16 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-UNK · INNOV-THIN · CLAIMS-SPARSE · TYPE-FRNCORP · SPAN-YRS · BOOK-RICH

GRANTS-MICRO 16 grants
MID-PACK #17,737/49,997
PHOTO-FINISH Hanwha Q Cells
CPC-UNK CPC blank
INNOV-THIN 30.4/100
CLAIMS-SPARSE 1.0 claims/avg
TYPE-FRNCORP Foreign Corp
SPAN-YRS 2022–2025 · 4y
BOOK-RICH 8/10 fields

Nearest grant-volume peer: Hanwha Q Cells GMBH (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Healthlead’s 30.4 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 9.8 pts (32%) Velocity 20.0 pts (66%) Breadth 0.0 pts (0%) Claim depth 0.6 pts (2%)

Qualcomm Incorporated · highest

85
Healthlead · this assignee

30
3D Lighting… · lowest

7

What this shows Healthlead's Innovation Score is 30.4/100 (34th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Healthlead?

Each dot is one of Healthlead’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Healthlead’s own 1.0 claims/patent is at or below the 13.4 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Healthlead vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Healthlead's grants concentrate

Healthlead Corporation Limited is a focused PatentsView assignee: 0 CPC subclasses . Peak complete grant year is 2023 (10 grants) versus a trough of 2 in 2022. By volume, Healthlead sits between Hanwha Q Cells GMBH and HID Global CID SAS.

Healthlead's three-year grant acceleration

Healthlead Corporation Limited shows 12 grants in 2022–2024 against only 0 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Hanwha Q Cells

16
Hass

16
Hcmed Innovations

16
HDT Bio

16
HED Sarl

16
HEP Tech

16
Heraeus Quartz No…

16
HID Global CID SAS

16
Healthlead ◀

16

What this shows Healthlead holds 16 patents at rank #17,731, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Healthlead

By rank, the assignees closest to #17,731 in granted patent volume.

Healthlead's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

30 34th percentile higher than 34% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2022–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2022–2019 baseline. Full figures in the table below.

View data table

Healthlead Corporation Limited patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2022	2	12.5%
2023	10	62.5%
2025partial year	4	25.0%

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Healthlead Corporation Limited's patent record in context - here's where to go next.

Ranked #17,737 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Healthlead Corporation Limited against Hanwha Q Cells GMBH, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 30.4/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.